A study published in Nature Medicine delineates how APOE4 homozygosity distinctly accelerates Alzheimer’s disease pathology and biomarkers from the age of 55, suggesting a unique form of the disease and a potential focus for targeted therapies.
FDA picks apart BrainStorm’s potential ALS treatment ahead of Wednesday adcomm
The unmet need for patients with the progressive neurodegenerative disease ALS, or amyotrophic lateral sclerosis, is undoubtedly high. But the FDA is drawing the line
September 26, 2023